Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5788562 | 0.94 | SLC34A1 (0.39) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL5790236 | 0.94 | SLC34A1 (0.39) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL5806010 | 0.94 | SLC34A1 (0.39) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL2931769 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL28402733 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL5792400 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL1251343 | 0.94 | SLC34A1 (0.46) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL33551 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL16701256 | 0.94 | SLC34A1 (0.46) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL5787353 | 0.89 | SLC34A1 (0.36) | SLC34A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118120923-A | Natural nano zinc supplement agent and preparation method and application thereof | 中国海洋大学三亚海洋研究院 | 2024-06-04 | — | — | CN | claimed |
| CN-118120923-A | Natural nano zinc supplement agent and preparation method and application thereof | 中国海洋大学三亚海洋研究院 | 2024-06-04 | — | — | CN | disclosed |
| CN-111693717-A | Rapid immunoassay kit and detection method for ferritin in serum | 江苏拜明生物技术有限公司 | 2020-09-22 | — | — | CN | disclosed |
| US-9512095-B2 | Polymorph forms of desazadesferrithiocin analogs | FERROKIN BIOSCIENCES, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160024034-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | FERROKIN BIOSCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| EP-2970162-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | Ferrokin Biosciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150299151-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | FERROKIN BIOSCIENCES, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2928469-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | Ferrokin Biosciences, Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| US-8993606-B2 | Oral formulations for treating metal overload | FERROKIN BIOSCIENCES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2787994-A1 | ORAL FORMULATIONS FOR TREATING METAL OVERLOAD | Ferrokin Biosciences, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20030015467-A1 | Microbiological water filter | JOHNSTON ARTHUR W (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002055704-A2 | PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME | CURAGEN CORP (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-1214273-A1 | MICROBIOLOGICAL WATER FILTER | Watervisions International, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001014257-A1 | MICROBIOLOGICAL WATER FILTER | WATERVISIONS INTERNATIONAL, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| US-6187192-B1 | WATER CONTAINING BACTERIA AND/OR VIRUSES IS PASSED THROUGH A PURIFICATION MATERIAL COMPOSED OF APATITE AND ABSORPTION MEDIA IN A FIXED BINDER MATRIX | WATERVISIONS INTERNATIONAL, INC. | 2001-02-13 | — | — | US | disclosed |
| US-6180016-B1 | MIXTURE OF APATITE IN BINDER | WATERVISIONS INTERNATIONAL, INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0131946-B1 | CRYSTALLINE FERROALUMINOPHOSPHATES | UNION CARBIDE CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4744885-A | Hydro-carbon conversion using ferroaluminophosphates | UNION CARBIDE CORPORATION (US) | 1988-05-17 | — | — | US | disclosed |
| US-4554143-A | CATALYSTS, ADSORBENTS, MOLECULAR SIEVES | UNION CARBIDE CORPORATION (US) | 1985-11-19 | — | — | US | disclosed |
| EP-0131946-A2 | Crystalline ferroaluminophosphates | UNION CARBIDE CORPORATION (US) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299151-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | SLC39A14, FTH1, SLC40A1 | SLC34A1 102/4885LMNA 2241/4885 |
| US-20160024034-A1 | POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS | SLC39A14, FTH1, SLC40A1 | SLC34A1 102/4885LMNA 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.